CROSSJECT: First step of the industrialization of ZENEO®
Chenove, June 11, 2014 - CROSSJECT (ISIN: FR0011716265, Ticker: ALCJ), designer of the needle-free injection system ZENEO®, takes a first key step toward industrialization by finalizing the setting up of the central elements of its production line. Thus, the extension of the line will rely on these manufacturing elements to obtain the components of ZENEO®.
The industrial production line includes notably two main operational elements: the thermal treatment chain for glass tubes and the moulds to produce ZENEO®'s components. The assembling and the flow management of the device will be the final step of the chain to ensure it is ready for operating.
Patrick Alexandre, President and founder of CROSSJECT declares: "We are very happy that we took this crucial step in the setting up of the production of ZENEO® on an industrial scale, in accordance with our plansg announced during our stock exchange listing. As an involved actor in developing the local industrial system, we also moved our thermal treatment unit to the French region of Bourgogne/Franche-Comté. With these advancements we are confident that we are moving ahead with our business plan."
The thermal treatment chain, a key element of ZENEO®'s manufacturing was moved from Switzerland to France. It carries out a high-tech thermal treatment of pharmaceutical glassware so that it can withstand the pressure during the injection. This step is strategically important for the manufacturing of ZENEO® as the glass tube is a central and complex component of the device. All the moulds were also repackaged and can be useful to the production of ZENEO® that will be used for clinical trials before receiving marketing approval. CROSSJECT has the production capacities necessary for the commercialization of ZENEO® which is expected in 2015. The production capacities will be completed by the set up of the assembly line and the supply-chain.
Contact
Crossject
Patrick Alexandre / Timothée Muller
info@crossject.com
Citigate Dewe Rogerson
Laurence Bault /Lucie Larguier
+33 (0)1 53 32 84 78 / 84 75
laurence.bault@citigate.fr
lucie.larguier@citigate.fr
About Crossject · www.crossject.com
Crossject is using its world-leading needle-free injection system, ZENEO(TM) to develop an attractive pipeline of high value SUPERGENERICS or New Therapeutics Entities. These needle-free products, which are based on well-known injectable drugs (chemicals & biologics), are designed to enhance patient safety, compliance and comfort.
Crossject's needle-free, pre-filled, single-use ZENEO (TM) injection systems are unique in that they can be tailored to deliver drugs intra-dermally, subcutaneously and intramuscularly. This means that ZENEO(TM) can allow a wide range of drugs and vaccines for a broad range on indications to be developed and approved in a very short period of time. Outside its own portfolio of SUPERGENERICS, Crossject anticipates partnering ZENEO with other pharma/biotech looking to improve the life cycle management of their key drugs or biologics.
CROSSJECT is listed on Alternext Paris (Ticker: ALCJ, ISIN: FR0011716265)
